Equities

Cytokinetics Inc

Cytokinetics Inc

Actions
  • Price (EUR)49.20
  • Today's Change-0.80 / -1.60%
  • Shares traded40.00
  • 1 Year change+64.00%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024 08:38 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments615783472
Total Receivables, Net1.280.1552
Total Inventory------
Prepaid expenses121212
Other current assets, total------
Total current assets628795536
Property, plant & equipment, net148163146
Goodwill, net------
Intangibles, net------
Long term investments4147152
Note receivable - long term------
Other long term assets8.009.697.19
Total assets8241,015841
LIABILITIES
Accounts payable222621
Accrued expenses615749
Notes payable/short-term debt000
Current portion long-term debt/capital leases111.000.50
Other current liabilities, total9.561.081.04
Total current liabilities1038572
Total long term debt608611144
Total debt619612144
Deferred income tax------
Minority interest------
Other liabilities, total500427382
Total liabilities1,2111,123597
SHAREHOLDERS EQUITY
Common stock0.100.090.08
Additional paid-in capital1,7261,4821,452
Retained earnings (accumulated deficit)(2112)(1586)(1208)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total(0.01)(3.59)(0.87)
Total equity(386)(108)244
Total liabilities & shareholders' equity8241,015841
Total common shares outstanding1029585
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.